ImmunityBio & Patrick Soon-Shiong

ImmunityBio: ImmunityBio is facing a securities class action lawsuit for allegedly making misleading claims about its product Anktiva, which caused its stock price to drop and market capitalization to decrease by nearly $2 billion.

Patrick Soon-Shiong: Patrick Soon-Shiong, executive chairman and Chief Scientific and Medical Officer of ImmunityBio, is accused of materially overstating Anktiva's capabilities, leading to the lawsuit.

ImmunityBio: ImmunityBio is the defendant in a class action lawsuit alleging that its statements about Anktiva's capabilities were materially false and misleading, which could negatively impact its stock price and reputation.

Patrick Soon-Shiong: Patrick Soon-Shiong is a defendant in the class action lawsuit, accused of materially overstating Anktiva's capabilities.

ImmunityBio: ImmunityBio is the defendant in a securities class action lawsuit, facing allegations of making false and misleading statements regarding Nogapendekin alfa inbakicept's capabilities, which could negatively impact its stock price and reputation.

Patrick Soon-Shiong: Patrick Soon-Shiong is a defendant in the lawsuit, accused of materially overstating Nogapendekin alfa inbakicept's capabilities, which could harm his professional reputation.

ImmunityBio: ImmunityBio is the defendant in a class action lawsuit alleging that its officers made materially false and misleading statements regarding Nogapendekin alfa inbakicept's capabilities, leading to investor losses.

Patrick Soon-Shiong: Defendant Soon-Shiong is alleged to have materially overstated Nogapendekin alfa inbakicept's capabilities, which is a central claim in the class action lawsuit against ImmunityBio.